Tuberculosis is an infectious-contagious disease that is still considered a major public health problem worldwide. Brazil is one of the 22 countries in the world responsible for 80% of the cases of the disease, and the highest incidence rates are observed in the North, Southeast and Northeast regions. The standard treatment regimen is composed of rifampicin, isoniazid, pyrazinamide and ethambutol. The clinical outcome is associated with the blood concentrations of these drugs after the use of therapeutic doses, however, despite the high incidence of the Brazilian disease, the concentrations of these drugs have not been evaluated in these patients, which is relevant mainly for rifampicin, given the high variability of concentrations in biological fluids after therapy. Therefore, a prospective case study was carried out to determine the concentrations of rifampicin by high performance liquid chromatography in patients with active tuberculosis treated in the city of Belém. Fifty patients were included in the study, however, there was a loss of clinical follow-up of 20 patients (40%), whose main reason was the abandonment of treatment. The social and demographic aspects of the others indicate a higher occurrence of the disease in males, low education, residents in the metropolitan area of Belém and in the productive age group. Rifampicin concentrations in the two treatment phases ranged from 0.6 μg / ml to 0.73 μg / ml. There was no significant difference in blood drug concentrations between treatment phases, however, rifampicin levels were significantly higher in women.
|
